MODUS

Modus is a Swedish biotechnology company that is developing its proprietary polysaccharide sevuparin as a potential treatment for several major healthcare needs including sepsis/septic shock and other disorders with severe systemic inflammation such as severe malaria, as well as states of anemia, related to chronic inflammation such as kidney disease. There is a great need for new treatments that can effectively treat these conditions. Modus' ambition is to create a paradigm shift in the care of these diseases, where sevuparin could provide therapeutic benefits... An important part of Modus' strategy is to attract partnerships and buyers for sevuparin by creating product value in our clinical research. We believe that product value is best created through robust clinical data with value-building milestones to enable further value build with a partner that already has presence in the therapy area and its market. A significant such milestone is after the completion of the phase IIa..

Primary location: Stockholm